impact factor
logo
 

Reviews

 

Type-III interferons in Sjögren’s syndrome


1, 2

 

  1. Department of Pathophysiology, and Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Greece.
  2. Department of Pathophysiology, and Academic Joint Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens, Greece. agtzi@med.uoa.gr

CER13536
2020 Vol.38, N°4 ,Suppl.126
PI 0245, PF 0252
Reviews

Free to view
(click on article PDF icon to read the article)

PMID: 32896259 [PubMed]

Received: 08/05/2020
Accepted : 01/06/2020
In Press: 02/09/2020
Published: 23/10/2020

Abstract

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease characterised by aberrant activation of innate and adaptive immune responses. Part of this hyper-activation is due to the interferon (IFN) system. Deregulated expression and activity of the type-I IFN system has been extensively studied in pSS. Type-III interferons (IFNs) are the latest addition to the IFN family, and exhibit potent anti-viral functions, similarly to type-I IFNs. More recently they have started to attract attention as key modulators in the interface of innate and adaptive immunity and chronic inflammation. Deregulated expression of type-III IFNs has been demonstrated in various autoimmune diseases over the last ten years. The scope of this review is to summarise recent findings regarding the biology of type-III IFNs in pSS. We highlight factors that regulate their induction, their downstream effects, their similarities and differences with type-I IFNs and their possible modes of action in Sjögren’s syndrome. Finally, we discuss their potential benefits as targets for therapeutic intervention.

Rheumatology Article